Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE Highlights
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Tumor mutational burden (TMB) emerges as a promising Prognostic and Predictive biomarker in multiple diseases for immune monitoring. Several studies have demonstrated the potential clinical utility of TMB as a biomarker of immune checkpoint blockade in multiple tumor types. TMB has been correlated with response to immunotherapy use in patients treated with immune checkpoint blockade. Therefore, TMB is required to accurately predict responses to immunotherapy. Equipped with world-leading technology platforms and professional scientific staff in the field of Biomarker Development, Creative Biolabs is glad to apply its special expertise in TMB biomarker discovery to help our worldwide clients with their cutting-edge research projects.
TMB is a measurement that quantifies the total number of somatic coding mutations by tumor cells, is emerging as a promising biomarker for immunotherapy response in cancer patients. In theory, a higher TMB increases the probability of tumor neoantigen production and therefore, the likelihood of immune recognition and tumor cell killing. TMB generally correlates with response to anti-PD-1 therapies, supported by a pooled analysis of 27 tumor types. A large number of significant ongoing research have evaluated the performance of TMB as a predictive biomarker to guide immunotherapy selection and management. TMB can be quantitated by several next-generation sequencing (NGS)-based sequencing technologies. Whole-exome sequencing (WES) allows comprehensive measurement of TMB and is considered the gold standard. However, due to the high cost of the large genomic space sequenced, WES is mainly used in research settings. In the clinical setting, instead, targeted gene panels of various genomic sizes are emerging as the routine technology for TMB assessment.
With our state-of-the-art technology and industry-leading expertise, Creative Biolabs has developed an unparalleled Immune Monitoring Platform. We offer accurate and effective solutions for researchers who are committed to TMB analysis for biomarker development. Our scientists have accumulated extensive experience in employing WES and targeted NGS panels for TMB biomarker discovery in a time-effective and cost-effective manner. Comprehensive coverage of tumor-related variants and optimized bioinformatics approach enable robust analysis of TMB.
In terms of the extensive experience in biomarker discovery, Creative Biolabs is proud to offer our clients TMB biomarker discovery service with the best quality and most competitive price. For more information on TMB biomarker discovery, please feel free to contact us and further discuss with our scientists.
Reference
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
